JP2002518346A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518346A5
JP2002518346A5 JP2000554400A JP2000554400A JP2002518346A5 JP 2002518346 A5 JP2002518346 A5 JP 2002518346A5 JP 2000554400 A JP2000554400 A JP 2000554400A JP 2000554400 A JP2000554400 A JP 2000554400A JP 2002518346 A5 JP2002518346 A5 JP 2002518346A5
Authority
JP
Japan
Prior art keywords
composition
tables
group
patient
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518346A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/013789 external-priority patent/WO1999065522A1/en
Publication of JP2002518346A publication Critical patent/JP2002518346A/ja
Publication of JP2002518346A5 publication Critical patent/JP2002518346A5/ja
Pending legal-status Critical Current

Links

JP2000554400A 1998-06-17 1999-06-17 Hla結合ペプチドおよびそれらの用途 Pending JP2002518346A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9858498A 1998-06-17 1998-06-17
US09/098,584 1998-06-17
PCT/US1999/013789 WO1999065522A1 (en) 1998-06-17 1999-06-17 Hla binding peptides and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010004446A Division JP2010090167A (ja) 1998-06-17 2010-01-12 Hla結合ペプチドおよびそれらの用途

Publications (2)

Publication Number Publication Date
JP2002518346A JP2002518346A (ja) 2002-06-25
JP2002518346A5 true JP2002518346A5 (OSRAM) 2006-08-10

Family

ID=22269985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000554400A Pending JP2002518346A (ja) 1998-06-17 1999-06-17 Hla結合ペプチドおよびそれらの用途
JP2010004446A Pending JP2010090167A (ja) 1998-06-17 2010-01-12 Hla結合ペプチドおよびそれらの用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010004446A Pending JP2010090167A (ja) 1998-06-17 2010-01-12 Hla結合ペプチドおよびそれらの用途

Country Status (8)

Country Link
EP (2) EP1089757B1 (OSRAM)
JP (2) JP2002518346A (OSRAM)
AT (1) ATE429247T1 (OSRAM)
AU (1) AU4577899A (OSRAM)
CA (1) CA2330824A1 (OSRAM)
DE (1) DE69940774D1 (OSRAM)
ES (1) ES2326146T3 (OSRAM)
WO (1) WO1999065522A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
WO2001041788A1 (en) * 1999-12-10 2001-06-14 Epimmune, Inc. INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
KR20160037196A (ko) 2013-07-31 2016-04-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 종양 연관된 탄수화물 항원을 표적으로 하는 암을 치료하고 예방하기 위한 조성물과 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン,インコーポレイティド Hla−a2.1結合ペプチドおよびそれらの使用
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン T細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン

Similar Documents

Publication Publication Date Title
JP2001521739A5 (OSRAM)
IL142905A0 (en) Functional antagonists of hedgehog activity
JP2002506648A5 (OSRAM)
JP2004517472A5 (OSRAM)
EP1917970A3 (en) Hla binding peptides and their uses
JP2002527052A5 (OSRAM)
JPH1045637A5 (OSRAM)
WO2000073316A3 (en) Virus immunologic determinants
EP1378245A3 (en) Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis. Their use in a vaccine
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
CA2081028A1 (en) Cd2 binding domain of lymphocyte function associated antigen 3
FI940054A0 (fi) Peptider av humant papillomavirus foer anvaendning i kompositioner som inducerar human T-cellsvar
NO20101441L (no) Tolerogent peptid og farmasoytisk preparat inneholdende det samme
AU6769998A (en) Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
WO2002004018A3 (en) Mid-life vaccine and methods for boosting anti-mycobacterial immunity
JP2003525623A5 (OSRAM)
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
JP2003508328A5 (OSRAM)
JP2001513504A5 (OSRAM)
JP2004534810A5 (OSRAM)
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
AU6001100A (en) Viral protein binding compositions and methods
DE69230932D1 (de) Depotzubereitung
AU2002225533A1 (en) Efficient expression of plasmodium apical membrane antigen 1 in yeast cells
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken